ClinicalTrials.gg
CompletedNCT00934648Updated Jun 10, 2014Results posted

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

A Phase 4 interventional study of rituximab [MabThera/Rituxan] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 5 sites in Morocco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-10.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
104th of 113
15 · median 130
Started
2007
with 8 others
Phase 4
38 of 113
3 open now
Registered
39th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 104th largest by enrollment, is one of 9 that started in 2007, is one of 38 in phase 4, and was the 39th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate. Eligible patients will receive MabThera (1000mg by intravenous infusion) on days 1 and 15, and background methotrexate (oral or subcutaneous dose of 10-25mg weekly). After the initial study period of 24 weeks, eligible patients may receive up to 3 re-treatments with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, >=18 years of age;
  • receiving out-patient treatment;
  • experienced an inadequate response to previous or current treatment with methotrexate.

Exclusion criteria

Exclusion Criteria:

  • rheumatic disease other than RA, or significant systemic involvement secondary to RA;
  • history of, or current, inflammatory joint disease other than RA;
  • previous treatment with any cell-depleting therapies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab [MabThera/Rituxan] · Drug: methotrexate

Interventions

  • Drugrituximab [MabThera/Rituxan]

    Drug page: Rituximab

    1000mg iv on days 1 and 15

  • 10-25mg weekly

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Adverse Event (AE)

    Time frame: Week 104

Secondary outcomes

  1. Disease Activity Score Based on 28-Joint Count (DAS28)

    DAS28 was calculated from the number of swollen joints and tender joints using the 28 joint count; the erythrocyte sedimentation rate (ESR) measured in millimeters per hour \[mm/hr\]); and the Patient's Global Assessment of disease activity (participant-rated visual analog assessment \[VAS\]) with transformed scores with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. Overall, a DAS28 score of less than or equal to (≤) 3.2 equals (=) low disease activity, and a DAS28 score of greater than (\>) 3.2 to 5.1 = moderate to high disease activity.

    Time frame: Day 1 and Week 24

  2. Percentage of Participants With a DAS28 Response by European League Against Rheumatism (EULAR) Category

    DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

    Time frame: Screening, Day 1, and Weeks 24 and 104

  3. Percentage of Participants With Changes in Bone Density

    Change in bone density in participants untreated with bisphosphonates was classified as percentage of participants with osteoporosis, osteopenia, or normal. In some participants, no determinations were available.

    Time frame: Screening, Weeks 48 and 104

07

Results

Posted Jun 10, 2014

Participant flow

Participant flow — Overall Study
MilestoneRituximab 1000 Milligrams (mg)
Started15
Completed6
Not completed9
Withdrew: Failure to return8
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With an Adverse Event (AE)
Time frame:
Week 104
Reported as:
Number · percentage of participants
Percentage of Participants With an Adverse Event (AE)
percentage of participantsRituximab 1000 mg
Percentage of Participants With an Adverse Event (AE)26.7
SecondaryDisease Activity Score Based on 28-Joint Count (DAS28)

DAS28 was calculated from the number of swollen joints and tender joints using the 28 joint count; the erythrocyte sedimentation rate (ESR) measured in millimeters per hour \[mm/hr\]); and the Patient's Global Assessment of disease activity (participant-rated visual analog assessment \[VAS\]) with transformed scores with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. Overall, a DAS28 score of less than or equal to (≤) 3.2 equals (=) low disease activity, and a DAS28 score of greater than (\>) 3.2 to 5.1 = moderate to high disease activity.

Time frame:
Day 1 and Week 24
Reported as:
Mean · scores on a scale
Disease Activity Score Based on 28-Joint Count (DAS28)
scores on a scaleRituximab 1000 mg
Day 15.79 ± 1.03
Week 244.41 ± 1.88
SecondaryPercentage of Participants With a DAS28 Response by European League Against Rheumatism (EULAR) Category

DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders: change from baseline greater than (\>)1.2 with DAS28 less than or equal to (≤)3.2; moderate responders: change from baseline \>1.2 with DAS28 \>3.2 to ≤5.1 or change from baseline \>0.6 to ≤1.2 with DAS28 ≤5.1; non-responders: change from baseline ≤0.6 or change from baseline \>0.6 and ≤1.2 with DAS28 \>5.1.

Time frame:
Screening, Day 1, and Weeks 24 and 104
Reported as:
Number · percentage of participants
Percentage of Participants With a DAS28 Response by European League Against Rheumatism (EULAR) Category
percentage of participantsRituximab 1000 mg
≤3.2 at Screening0
>3.2 and ≤5.1 at Screening22.2
>5.1 at Screening77.8
≤3.2 at Day 10
>3.2 and ≤5.1 at Day 133.3
>5.1 at Day 166.7
≤3.2 at Week 2437.5
>3.2 and ≤5.1 at Week 2437.5
>5.1 at Week 2425.0
≤3.2 at Week 10433.3
>3.2 and ≤5.1 at Week 10433.3
>5.1 at Week 10433.3
SecondaryPercentage of Participants With Changes in Bone Density

Change in bone density in participants untreated with bisphosphonates was classified as percentage of participants with osteoporosis, osteopenia, or normal. In some participants, no determinations were available.

Time frame:
Screening, Weeks 48 and 104
Reported as:
Number · percentage of participants
Percentage of Participants With Changes in Bone Density
percentage of participantsRituximab 1000 mg
Osteoporosis, Screening20
Osteopenia, Screening46.7
Normal, Screening0
Not determined, Screening33.3
Osteoporosis, Week 486.7
Osteopenia, Week 4813.3
Normal, Week 486.7
Not determined, Week 4873.3
Osteoporosis, Week 1040
Osteopenia, Week 10440
Normal, Week 1040
Not determined, Week 10460

Adverse events

Collected over Adverse events were collected from signing of informed consent through the end of the follow-up period (Week 104).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab 1000 mg—0/15 (0%)4/15 (26.7%)
Most frequent other events
Most frequent other events
EventRituximab 1000 mg
FeverGeneral disorders1/15
Scalp infectionInfections and infestations1/15
RashSkin and subcutaneous tissue disorders1/15
Rash of faceSkin and subcutaneous tissue disorders1/15
Diffuse skin rashSkin and subcutaneous tissue disorders1/15
DyspneaRespiratory, thoracic and mediastinal disorders1/15
Tightening of throat and tongueRespiratory, thoracic and mediastinal disorders1/15
Difficulty breathingRespiratory, thoracic and mediastinal disorders1/15

Baseline characteristics

Intent-to-Treat (ITT) population: all participants who received any part of an infusion.

Age, Continuous
Age, Continuous(years)Rituximab 1000 mg
Mean37 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab 1000 mg
Female10
Male5
08

Study locations

5 sites
  • Casablanca, 20000, Morocco
  • Casablanca, 20100, Morocco
  • Marrakech, 40000, Morocco
  • Rabat, 10150, Morocco
  • Salé, 15045, Morocco
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2009
First posted
Jul 8, 2009
Start
Oct 2007
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Jun 10, 2014
Last update
Jun 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00934648
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jul 8, 2009
Start date
Oct 2007
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Jun 10, 2014
Last update
Jun 10, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion